Likitanci da magunguna · Ayyukan da ake kan yi da ci gaba
Inhibrx Ta Sanar da Sabbin Bayanan Asibiti na Ozekibart (INBRX-109) a Cikin Cutar Ewing Sarcoma
- Hadin gwiwar Ozekibart a cutar Ewing Sarcoma wacce ta dawo ko kuma ba ta amsa magani ba ta samu kason ORR na 62.7%; - Kason DCR ya kai 86.3%, tare da ganin an samu amsa mai dorewa a marasa lafiya da suka sha wahala kafin su fara maganin SAN DIEGO, Nuwamba 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" ko kuma "Kamfanin"), wani kamfani da ke matakin gwajin asibiti...
Asalin tushe
Karanta tushen — prnewswire.com ↗Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.